Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.72 |
| ▸ | APP | P05067 | 2/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TLR4 | O00206 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | HPD | P32754 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860962 | 0.85 | MAOB (0.70) | MAOBAPPNR4A2MAOACYP3A4 | |
| 3-(Benzyloxy)Aniline SCHEMBL291445 | 0.84 | MAOB (1.00) | MAOBAPPNR4A2MAOACYP3A4 | |
| 3-(Benzyloxy)Aniline SCHEMBL29428912 | 0.84 | MAOB (1.00) | MAOBAPPNR4A2MAOACYP3A4 | |
| SCHEMBL11087733 | 0.83 | MAOB (0.63) | MAOBAPPMAOACYP3A4TP53 | |
| SCHEMBL810623 | 0.83 | MAOB (0.72) | MAOBAPPNR4A2MAOACYP3A4 | |
| SCHEMBL810677 | 0.83 | MAOB (0.72) | MAOBAPPMAOACYP3A4TP53 | |
| SCHEMBL4639670 | 0.83 | MAOB (0.72) | MAOBAPPMAOACYP3A4TP53 | |
| 3-(Benzyloxy)Aniline SCHEMBL11263814 | 0.82 | MAOB (0.96) | MAOBAPPNR4A2MAOACYP3A4 | |
| SCHEMBL4638967 | 0.82 | MAOB (0.66) | MAOBAPPMAOACYP3A4TP53 | |
| SCHEMBL9795738 | 0.81 | MAOB (0.70) | MAOBAPPCYP3A4TP53SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2020-04-16 | — | — | US | disclosed |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | Basilea Pharmaceutica International AG (CH) | 2019-11-05 | — | — | US | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-06-28 | — | — | US | disclosed |
| EP-3307725-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-04-18 | — | — | EP | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016198691-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | BASILEA PHARMACEUTICA AG (CH) | 2016-12-15 | — | — | WO | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-0113922-A2 | Process for the manufacture of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113921-A2 | Process for the manufacture of stable solutions of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| US-3956264-A | Basic azo dyestuffs having indolyl-methyleneamino substituent in the diazo component | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | MAOB 2280/4885APP 3116/4885NR4A2 2777/4885 |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | ABCB11, ABCC1, ABCC3 | MAOB 2350/4885APP 3106/4885NR4A2 2784/4885 |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | MAOB 2350/4885APP 3106/4885NR4A2 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.